PROTACs

PROTACs (Proteolysis Targeting Chimeras) represent a novel therapeutic strategy that utilizes bifunctional molecules to target specific proteins for degradation. Unlike traditional inhibitors that merely block protein function, PROTACs recruit an E3 ubiquitin ligase to bind to a target protein, leading to its ubiquitination and subsequent degradation via the proteasome. This method allows for the precise removal of disease-associated proteins, including those traditionally deemed "undruggable." The dual-binding nature of PROTACs—connecting a target protein-ligand with an E3 ligase ligand via a linker—enables high specificity and reduced side effects. PROTACs are highly versatile, offering transformative potential in treating a wide range of diseases, including cancers and neurological disorders.